Therapeutic Inhibition of Angiogenesis
The idea of antiangiogenesis as a therapeutic strategy has been around for several decades (1 ). Vigorously pursued as a novel anticancer strategy (reviewed in (2 –6 ), it is now widely considered to be a promising approach to the treatment of a range of pathologies of which uncontrolled vascular proliferation is a component (see Table 1 ). To date, therapeutic benefit has been achieved with antiangiogenic therapy in the treatment of life-threatening infantile hemangioma, pulmonary hemangiomatosis, and in the treatment of some vascular tumors (7 ,8 ). Table 1 Table 1
Pathologies Likely to Benefit from Therapeutic Intervention in Angiogenesis | |
|---|---|
Excess angiogenesis | Insufficient angiogenesis |
Arthritis | Angiology |
Inflammatory, | Vascular malformation |
Rheumatoid, | Hemifacial micromia |
Kaposi's sarcoma | Bone fracture nonunion |
Leukemia, lymphoma, and myeloma | Chronic wounds |
Macular degeneration | Ischemia/infarction |
Paget's disease | Cerebral |
Psoriasis | Intestinal |
Retinopathy (and its vascular complications) | Myocardial |
Proliferative | Peripheral |
Of prematurity | Pyrogenic granuloma |
Solid carcinomas | Ulcer |
Primary | Duodenal |
Secondary (metastasis) | Gastric |
Vascular tumors | |
Hemangioma | |
Capillary | |
Juvenile (infantile) | |
Hemangiomatosis | |
Hemagioblastoma | |
Other benign vascular proliferations |
相关文章
